Multi-parameter systematic strategies for predictive, preventive and personalised medicine in cancer
Open Access
- 22 January 2013
- journal article
- Published by Springer Nature in EPMA Journal
- Vol. 4 (1) , 2
Abstract
Cancer is a complex disease that causes the alterations in the levels of gene, RNA, protein and metabolite. With the development of genomics, transcriptomics, proteomics and metabolomic techniques, the characterisation of key mutations and molecular pathways responsible for tumour progression has led to the identification of a large number of potential targets. The increasing understanding of molecular carcinogenesis has begun to change paradigms in oncology from traditional single-factor strategy to multi-parameter systematic strategy. The therapeutic model of cancer has changed from adopting the general radiotherapy and chemotherapy to personalised strategy. The development of predictive, preventive and personalised medicine (PPPM) will allow prediction of response with substantially increased accuracy, stratification of particular patient groups and eventual personalisation of medicine. The PPPM will change the approach to tumour diseases from a systematic and comprehensive point of view in the future. Patients will be treated according to the specific molecular profiles that are found in the individual tumour tissue and preferentially with targeted substances, if available.Keywords
This publication has 99 references indexed in Scilit:
- Identification of Candidate Biomarkers for Early Detection of Human Lung Squamous Cell Cancer by Quantitative ProteomicsMolecular & Cellular Proteomics, 2012
- Intra-tumour heterogeneity: a looking glass for cancer?Nature Reviews Cancer, 2012
- mTOR Signaling in Growth Control and DiseaseCell, 2012
- Tumor Metastasis: Molecular Insights and Evolving ParadigmsCell, 2011
- Individual differences in prefrontal cortex function and the transition from drug use to drug dependenceNeuroscience & Biobehavioral Reviews, 2010
- Tumour‐infiltrating T‐cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature reviewThe Journal of Pathology, 2010
- The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphomaLeukemia, 2010
- The use of variations in proteomes to predict, prevent, and personalize treatment for clinically nonfunctional pituitary adenomasEPMA Journal, 2010
- A high-resolution map of transcription in the yeast genomeProceedings of the National Academy of Sciences, 2006
- Mass spectrometry-based proteomicsNature, 2003